Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

YieldMax AMD Option Income Strategy ETFTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

YieldMax AMD Option Income Strategy ETF vs Charles River Laboratories Intl. Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.66, while Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

AMDYCRL
Sector
Income / Options OverlayHealth
52-Week High
$59.52$282.00
52-Week Low
$29.80$145.57
Market Cap
$13.46B
Enterprise Value
$16.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AMD Option Income Strategy ETF

AMDY trades at $45.66, up 2.47% with a bearish technical signal from moving averages. The ETF generates high weekly distributions but faces concerns about NAV erosion during AMD volatility. Recent Seeking Alpha analysis rates it HOLD, noting the strategy works best when AMD rises gradually rather than accelerating sharply.

Outlook remains cautious due to structural NAV erosion risks. The high-yield strategy provides income opportunity but requires careful timing. Key risks include AMD's performance volatility and the ETF's call spread strategy limitations during market downturns.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax AMD Option Income Strategy ETF

AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.

Read more on AMDY

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL